Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PRMT3 | O60678 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9963475 | 0.78 | ALDH1A1 (0.48) | L3MBTL1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL9963477 | 0.73 | GAA (0.42) | PRMT3MAPTKDM4EKMT2AALDH1A1 | |
| SCHEMBL9963472 | 0.73 | LMNA (0.49) | L3MBTL1KDM4EKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL9963676 | 0.72 | PPID (0.46) | L3MBTL1MAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL8299375 | 0.70 | L3MBTL1 (0.49) | L3MBTL1KDM4EKMT2AALDH1A1 | |
| SCHEMBL9963478 | 0.69 | LMNA (0.46) | L3MBTL1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL9963505 | 0.69 | ALDH1A1 (0.52) | L3MBTL1MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL8230809 | 0.66 | TDP1 (0.50) | L3MBTL1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL13212070 | 0.65 | KMT2A (0.59) | L3MBTL1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL5464735 | 0.65 | HDAC1 (0.51) | MAPTKDM4EKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8203001-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8203001-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-20090258857-A1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258857-A1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258857-A1 | CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | L3MBTL1 739/4885PRMT3 902/4885MAPT 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.